Abstract
Please check all author names and their affiliations, and correct if necessary.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Notes
- 1.
Apart from EPF representing patients, involved stakeholder groups were healthcare professionals (Standing Committee of European Doctors (CPME), Pharmaceutical Group of the European Union (PGEU)), payers (Association Internationale de la Mutualité (AIM), European Social Insurance Platform (ESIP)), industry (European Federation of Pharmaceutical Industries and Associations (EFPIA), European Generic Medicines Association (EGA), European Self-Medication Industry (AESGP), European Association for Bioindustries (EuropaBio), European Association of Full-Line Wholesalers (GIRP)).
- 2.
Part of the training is inspired by a course ‘Introduction to Health Technology Assessment’ by the Institute of Public Health, University for Health Sciences, Medical Informatics and Technology, Hall in Tirol (Prof. Uwe Siebert).
- 3.
Other public partners involved in EUPATI are EURORDIS, European Genetic Alliance and European AIDS Treatment Group.
References
ADAPTSMART. Accelerated development of appropriate patient therapies a sustainable, multi-stakeholder approach from research to treatment-outcomes (2016). http://adaptsmart.eu/. Accessed 17 Aug 2016.
EATG. AIDS Treatment project. Press Conference. In: EATN (1996). http://www.eatg.org/wp-content/uploads/2016/05/1996vol5n6.pdf. Accessed 20 Nov 2016.
CORD. Affiliate/Group. http://www.raredisorders.ca/cord-membership/#section-id-157 (2016). Accessed 16 Nov 2016.
EMA. Patients and consumers (2016a). http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000317.jsp&mid=WC0b01ac058003500c. Accessed 16 Nov 2016.
EMA. Partners and networks (2016b). http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000212.jsp&mid=. Accessed 15 Sept 2016.
EmERGE. EmERGE mHealth platform. http://www.emergeproject.eu/. 2016. Accessed 07 Sept 2016.
EPF. Health Technology Assessment: European Patients’ Forum seminar report, European Patients’ Forum. 2010. http://www.eu-patient.eu/globalassets/library/conferenceseminarreports/hta-seminar-2010-brussels-report.pdf. Accessed 15 Sept 2016.
EPF. Patient involvement in Health Technology Assessment in Europe: results of the EPF survey. European Patients’ Forum. 2013. http://www.eu-patient.eu/globalassets/projects/hta/hta-epf-final-report2013.pdf. Accessed 16 Aug 2016.
EPF. European Patients’ Forum (2016). www.eu-patient.eu. Accessed 15 Sept 2016.
EUPATI. European Patients’ Academy on Therapeutic Innovation (2016a). http://www.patientsacademy.eu/. Accessed 16 Aug 2016.
EUPATI. European Patients’ Academy. 2016b. https://www.eupati.eu. Accessed 16 Aug 2016.
European Commission. High Level Pharmaceutical Forum—2005–2008—Final Report. European Commission. 2008. http://www.anm.ro/_/Final%20Conclusions%20and%20Recommendations%20of%20the%20High%20Level%20Pharmaceutical%20Forum.pdf. Accessed 18 Nov 2016.
European Commission. Report on the public consultation on the modalities of stakeholder consultation in the future Health Technology Assessment Network, European Commission. 2012. http://ec.europa.eu/health/technology_assessment/docs/cons_hta_network_results_en.pdf. Accessed 06 Sept 2016.
European Multiple Sclerosis Platform, European register for multiple sclerosis project report 2011–2014. 2016. http://www.emsp.org/wp-content/uploads/2015/06/140930-EUReMS-Report.pdf. Accessed 17 Aug 2016.
EURORDIS. The voice of 12,000 patients—experiences and expectations of rare disease patients on diagnosis and care in Europe. 2009. http://www.eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_FULLBOOKr.pdf. Accessed 17 Nov 2016.
EURORDIS. Access to orphan drugs (2016a). http://www.eurordis.org/content/access-orphan-drugs. Accessed 17 Nov 2016.
EURORDIS, Eurordis Summer School (2016b). http://www.eurordis.org/summer-school. Accessed 15 Sept 2016.
Health Equality Europe. Understanding Health Technology Assessment (HTA). Health equality Europe. 2008. http://img.eurordis.org/newsletter/pdf/nov-2010/58-1%20HEE%20Guide%20To%20HTA%20for%20Patients%20English.pdf. Accessed 15 Sept 2016.
IAPO. International Alliance of Patients’ Organizations. www.iapo.org.uk. 2016. Accessed 15 Sept 2016.
Marcus AD. Lessons from AIDS/HIV advocacy efforts. In: Health blog: the Wall Street Journal. 2011. http://blogs.wsj.com/health/2011/06/16/lessons-from-aidshiv-advocacy-efforts/. Accessed 16 Aug 2016.
MedTech Europe. 2015 Priorities of the “Patient-MedTech Dialogue”. Focus on Medtech. 2015. http://medical.technology/newsletternews/762/86. Accessed 17 Aug 2016.
NHC. The patient voice in value: the National Health Council patient-centered value model rubric. NHC. 2016. http://www.nationalhealthcouncil.org/sites/default/files/Value-Rubric.pdf. Accessed 18 Nov 2016.
Pivik J, Rode E, Ward C. A consumer involvement model for Health Technology Assessment in Canada. Health Policy. 2004;69:253–68.
SEED. Shaping European Early Dialogues. http://www.earlydialogues.eu/has/. 2015. Accessed 31 Oct 2016.
Wong-Rieger D. Patients as partners in HTA. 2013. http://www.ispor.org/meetings/neworleans0513/releasedpresentations/W20_Wong-Rieger.pdf. Accessed 16 Aug 2016.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Bedlington, N., Geissler, J., Houyez, F., Lightbourne, A., Maskens, D., Strammiello, V. (2017). Role of Patient Organisations. In: Facey, K., Ploug Hansen, H., Single, A. (eds) Patient Involvement in Health Technology Assessment. Adis, Singapore. https://doi.org/10.1007/978-981-10-4068-9_35
Download citation
DOI: https://doi.org/10.1007/978-981-10-4068-9_35
Published:
Publisher Name: Adis, Singapore
Print ISBN: 978-981-10-4067-2
Online ISBN: 978-981-10-4068-9
eBook Packages: MedicineMedicine (R0)